Theriva Biologics Inc. (TOVX)
AMEX: TOVX
· Real-Time Price · USD
0.49
-0.02 (-3.54%)
At close: Jul 24, 2025, 3:59 PM
-3.54% (1D)
| Bid | 0.48 |
| Market Cap | 4.43M |
| Revenue (ttm) | 154K |
| Net Income (ttm) | -24.81M |
| EPS (ttm) | -13.05 |
| PE Ratio (ttm) | -0.04 |
| Forward PE | -0.09 |
| Analyst | n/a |
| Dividends | n/a |
| Ask | 0.49 |
| Volume | 115,268 |
| Avg. Volume (20D) | 1,484,377 |
| Open | 0.50 |
| Previous Close | 0.51 |
| Day's Range | 0.48 - 0.50 |
| 52-Week Range | 0.40 - 7.25 |
| Beta | 0.82 |
| Ex-Dividend Date | n/a |
About TOVX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol TOVX
Website n/a
4 months ago
-20.59%
Theriva Biologics shares are trading lower after M...
Unlock content with
Pro Subscription
4 months ago
-40.44%
TOVX stock has given up its prior gain. Theriva Biologics shares were trading higher after the company announced VCN-01 was well tolerated with transient and reversible adverse events, meeting the primary safety endpoint.
2 years ago · proactiveinvestors.com
Theriva Biologics jumps on US FDA approval for pancreatic cancer treatmentTheriva Biologics Inc saw its shares surge over 70% higher in after-hours US trading following news that its lead clinical candidate, VCN-01, has been granted orphan drug designation by the US Food an...
